Barinthus Biotherapeutics (BRNS) Expected to Announce Earnings on Wednesday

Barinthus Biotherapeutics (NASDAQ:BRNS) is expected to be posting its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Barinthus Biotherapeutics to post earnings of ($0.45) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 6:00 PM ET.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.23). On average, analysts expect Barinthus Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Barinthus Biotherapeutics Trading Down 9.6%

Shares of BRNS opened at $1.19 on Tuesday. The business’s 50 day moving average is $1.27 and its 200 day moving average is $1.14. Barinthus Biotherapeutics has a 12-month low of $0.64 and a 12-month high of $2.92. The company has a market capitalization of $48.46 million, a PE ratio of -0.69 and a beta of -0.70.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Barinthus Biotherapeutics in a research report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Barinthus Biotherapeutics currently has an average rating of “Hold” and an average price target of $3.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. raised its holdings in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 192,461 shares of the company’s stock after purchasing an additional 100,000 shares during the period. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent quarter. Institutional investors and hedge funds own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.